



28 April 2016
EMA/297095/2016
Human Medicines Evaluation Division

Overview of (invented) names reviewed in April 2016 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 25-28 April 2016

	NRG meeting 03 Feb 2016		NRG meeting 06 April 2016		NRG meeting 01 June 2016		NRG meeting 06 Jul 2016		NRG meeting 21 Sep 2016		NRG meeting 23 Nov 2016		2016	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	27	35	48	52										
Justification for retention of (invented) name *	0	4	1	6										

*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.



	NRG meeting 03 Feb 2016		NRG meeting 06 April 2016		NRG meeting 01 June 2016		NRG meeting 06 Jul 2016		NRG meeting 21 Sep 2016		NRG meeting 23 Nov 2016		2016	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Total number of objections raised	72	39	113	90										
Criterion - Safety concerns														
Similarity with other (invented) name	62	33	108	86										
Conveys misleading therapeutic/pharmaceutical connotations	0	0	0	0										
Misleading with respect to composition	1	0	1	0										
Criterion - INN concerns														
Similarity with INN	3	3	2	3										
Inclusion of INN stem	0	0	0	1										
Criterion - Other public health concerns														
Unacceptable qualifiers	1	0	0	0										
Conveys a promotional message	1	0	1	0										
Appears offensive or has an inappropriate connotation	1	0	0	0										
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0										
Similarity between name of prodrug and related active substance	0	0	0	0										
Others	3	3	1	0										

See *Guideline on the [Acceptability of Names for Human Medicinal Products Processed through the Centralised Procedure \(EMA/CHMP/287710/2014\)](#)* for detailed explanations of criteria used.